Role of dopamine in the regulation of aldosterone and 18-hydroxycorticosterone secretion in man.
This study was designed to investigate dopaminergic mechanisms involved in the control of corticosteroid secretion. Administration of the dopamine agonist bromocriptine (2.5 mg three times a day for 4 days) to 10 normal males suppressed (p less than 0.01) plasma 18-hydroxycorticosterone (18-OHB) responses to upright posture, isometric handgrip exercise, furosemide administration and angiotensin II infusion without altering supine blood pressure, electrolytes or plasma cortisol. Plasma 18-OHB responses to adrenocorticotropic hormone infusion were not altered by bromocriptine treatment. These observations suggest that angiotensin-mediated 18-OHB and aldosterone secretion is selectively inhibited by dopaminergic mechanisms. Thus, dopamine and angiotensin II may operate as opposing factors in the control of aldosterone biosynthesis.
D015069:18-Hydroxycorticosterone / Q000097:blood*; D000324:Adrenocorticotropic Hormone; D000328:Adult; D000450:Aldosterone / Q000097:blood*; D000804:Angiotensin II; D001794:Blood Pressure; D001971:Bromocriptine; D003345:Corticosterone / Q000031:analogs & derivatives*; D004298:Dopamine / Q000502:physiology*; D004573:Electrolytes / Q000378:metabolism; D005665:Furosemide; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007537:Isometric Contraction; D008297:Male; D011187:Posture
D004573:Electrolytes; D000804:Angiotensin II; D001971:Bromocriptine; D000450:Aldosterone; D015069:18-Hydroxycorticosterone; D005665:Furosemide; D000324:Adrenocorticotropic Hormone; D004298:Dopamine; D003345:Corticosterone; D006854:Hydrocortisone